

Entitlement Offer closing date extended to 30 November 2023

On 25 October 2023, Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) announced the details of a non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$10 million.

Under the Entitlement Offer, eligible shareholders are able to subscribe for 2 new fully paid ordinary shares in Chimeric (**New Shares**) for every 3 fully paid ordinary shares in Chimeric held as at 7pm (Sydney time) on Tuesday, 31 October 2023 at the issue price of \$0.028 per New Share.

Chimeric advises that the closing date of the Entitlement Offer has been extended to 5 pm (Sydney time) on Thursday 30 November 2023 (**Extended Closing Date**). The Extended Closing Date is to ensure all eligible shareholders have an opportunity to participate in the Entitlement Offer, having regard to shareholder feedback received in relation to the Entitlement Offer.

Revised indicative timetable¹

The Extended Closing Date will have a consequential effect on the indicative timetable, including the date of allotment and issue of the New Shares under the Entitlement Offer which is now anticipated to occur on Thursday, 7 December 2023.

Event	Date
Announcement of the Entitlement Offer	Wednesday, 25 October 2023
Record Date for Retail Entitlement Offer (7.00 pm AEDT)	Tuesday, 31 October 2023
Information Booklet and Entitlement and Acceptance Form despatched	Thursday, 2 November 2023
Entitlement Offer opens	Thursday, 2 November 2023
Entitlement Offer closes (5.00 pm AEDT)	Thursday, 30 November 2023
New Shares quoted on a deferred settlement basis	Friday, 1 December 2023
Announcement of results of the Entitlement Offer	Thursday, 7 December 2023

¹All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.



Event	Date
Allotment of New Shares under the Entitlement Offer	Thursday, 7 December 2023
Despatch of holding statements for New Shares issued under the Entitlement Offer	Friday, 8 December 2023
Trading of New Shares under the Entitlement Offer commences	Friday, 8 December 2023

Electronic access

The information booklet (**Booklet**) under which the Entitlement Offer is made is available electronically at www.chimerictherapeutics.com. The entitlement and acceptance form attached to the electronic version of the Booklet must be used within Australia or New Zealand.

Further information is available at nreo.chimerictherapeutics.com.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

This announcement has been authorised by the Board of Chimeric.

Phillip Hains
Joint Company Secretary

Important information

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Chimeric does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.